ArticleLearning & memory (Cold Spring Harbor, N.Y.)2011
Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine.
Article in Learning & memory (Cold Spring Harbor, N.Y.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Multicenter 16-Week Randomized Double Blind Placebo-Controlled Evaluation of the Efficacy, Tolerability and Safety of Memantine Hydrochloride on Enhancing the Cognitive Abilities of Adolescents and Young Adults With Down Syndrome
Phase 1B Trial on Escalating Doses of Memantine in Down Syndrome
Who cites it
26 citing papers in PubMed, 46 citations in OpenAlex.
- Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial.Translational psychiatry · 2012Trial
- Current insights and prospects for the pathogenesis and treatment of clinical manifestations associated with Down syndrome through neurotransmitter, inflammatory, and oxidative stress pathways.Frontiers in pharmacology · 2025Review
- Toward the Identification of Neurophysiological Biomarkers for Alzheimer's Disease in Down Syndrome: A Potential Role for Cross-Frequency Phase-Amplitude Coupling Analysis.Aging and disease · 2023Review
- Development of treatments for Down syndrome.The Lancet. Neurology · 2022Article
- Prenatal treatment with rapamycin restores enhanced hippocampal mGluR-LTD and mushroom spine size in a Down's syndrome mouse model.Molecular brain · 2021Article
- Quantitative Analysis of Retinal Structure and Function in Two Chromosomally Altered Mouse Models of Down Syndrome.Investigative ophthalmology & visual science · 2020Article
- Integrative Analysis Extracts a Core ceRNA Network of the Fetal Hippocampus With Down Syndrome.Frontiers in genetics · 2020Article
- Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors.Nature communications · 2019Article
- On the Design of Broad-Based Neuropsychological Test Batteries to Assess the Cognitive Abilities of Individuals with Down Syndrome in the Context of Clinical Trials.Brain sciences · 2018Review
- Phosphoproteomic Alterations of Ionotropic Glutamate Receptors in the Hippocampus of the Ts65Dn Mouse Model of Down Syndrome.Frontiers in molecular neuroscience · 2018Article
- Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome.Neural plasticity · 2018Article
- The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome.Frontiers in cellular neuroscience · 2017Review
- Impact of Increased Astrocyte Expression of IL-6, CCL2 or CXCL10 in Transgenic Mice on Hippocampal Synaptic Function.Brain sciences · 2016Review
- Where Environment Meets Cognition: A Focus on Two Developmental Intellectual Disability Disorders.Neural plasticity · 2016Review
- Dendritic spine dysgenesis in autism related disorders.Neuroscience letters · 2015Review
- Extrasynaptic NMDA Receptor in Excitotoxicity: Function Revisited.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2015Review
- Protein dynamics associated with failed and rescued learning in the Ts65Dn mouse model of Down syndrome.PloS one · 2015Article
- Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations.Drug design, development and therapy · 2015Review
- Altered distribution of hippocampal interneurons in the murine Down Syndrome model Ts65Dn.Neurochemical research · 2015Article
- Glutamatergic transmission aberration: a major cause of behavioral deficits in a murine model of Down's syndrome.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The Ts65Dn mouse is the best-studied animal model for Down syndrome. In the experiments described here, NMDA-mediated or mGluR-mediated LTD was induced in the CA1 region of hippocampal slices from Ts65Dn and euploid control mice by bath application of 20 µM NMDA for 3 min and 50 µM DHPG for 5 min, respectively. We found that Ts65Dn mice display exaggerated NMDA-induced, but not mGluR-induced, LTD in the CA1 region of the hippocampus compared with euploid control animals. In addition, this abnormal level of LTD can be pharmacologically rescued by the NMDA receptor antagonist memantine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.